Comparison of the demographics of the patients with low versus high FGF7 protein levels showed no significant differences in age, race, body mass index (BMI), tumor histology, cancer stage, blood cancer antigen 125 (CA-125), or exposure to bevacizumab in their treatment regimen (Table 3). The gene discussed is FGF7; the disease is cancer.